Alzheimer’s drug pipeline is healthier than you think

OF all Medical challenges to which scientists have encountered, Alzheimer’s disease, the most common form of dementiawas one of the most delicate. Between 1995 and 2021, private money spent for Alzheimer’s research totaled $ 42.5 billion, but more than 140 trials failed to deliver a single drug capable of slowing down the disease. However, the tide can turn. There are two work drugs, offering modest advantages, on the market. A new review document suggests that others may soon follow.